US industry paints a gloomy picture as share prices tumble
This article was originally published in Clinica
Share prices in the US devices industry have seen a 12.5% decline in the first nine months of this year. Some sectors have been particularly badly hit, with businesses in the imaging devices market seeing nearly a quarter of their average value wiped off, as 23 of the 29 companies in that sector experienced declines.
You may also be interested in...
Celltrion has accelerated the development of its antiviral treatment for COVID-19 and aims to launch a rapid self-testing kit that could provide results within 15-20 minutes. The Korean firm also plans to develop a ‘super antibody’ to prepare for potential future pandemic situations.
Paracetamol, acetylcysteine and loperamide among list of OTC drugs deemed "essential" by Spain in the fight against coronavirus.
Mylan, in partnership with Indian firm Lupin, will be looking to rival Biogen and Sandoz by introducing an etanercept biosimilar in European markets following a positive opinion by the EMA’s CHMP on Mylan's application.